[go: up one dir, main page]

JP2007037885A - Apparatus and method for endermic drug delivery and manufacturing method of needle for endermic drug delivery apparatus - Google Patents

Apparatus and method for endermic drug delivery and manufacturing method of needle for endermic drug delivery apparatus Download PDF

Info

Publication number
JP2007037885A
JP2007037885A JP2005227584A JP2005227584A JP2007037885A JP 2007037885 A JP2007037885 A JP 2007037885A JP 2005227584 A JP2005227584 A JP 2005227584A JP 2005227584 A JP2005227584 A JP 2005227584A JP 2007037885 A JP2007037885 A JP 2007037885A
Authority
JP
Japan
Prior art keywords
needle
skin
drug delivery
drug
fine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005227584A
Other languages
Japanese (ja)
Other versions
JP4804827B2 (en
Inventor
Naoya Miyano
尚哉 宮野
Tetsuya Miyaji
哲也 宮地
Satoshi Konishi
聡 小西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2005227584A priority Critical patent/JP4804827B2/en
Publication of JP2007037885A publication Critical patent/JP2007037885A/en
Application granted granted Critical
Publication of JP4804827B2 publication Critical patent/JP4804827B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023Drug applicators using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046Solid microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an apparatus for endermic drug delivery which is painless and safety to a human body, easily disposable, capable of using for quite a lot of drugs, and easily manufactured at low cost. <P>SOLUTION: A needle device 2' having 200 μm of a fine needle is pushed on a skin 4 under normal pressure. Here is stratum corneum 4a, epidermal layer 4b, and corium layer 4c. Then the needle device 2' is pulled up to pull the fine needle out of the skin 4. Further, a pore 5 is temporarily formed on the skin 4 to reach the epidermal layer 4b. A drug 6 is supplied to the upper part of the formed pore 5 and penetrated under the skin through the pore 5. The drug may be applied on the pore 5. Additionally, positive and negative electrodes are put on the skin 4 when the drug 6 is supplied, and so the electric field fainter than usual iontophoresis is applied to enable the drug penetration to promote. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、薬剤を皮下に供給する経皮性薬剤配送装置及び該装置を使用した経皮性薬剤配送方法並びに該装置に用いる針装置の製造方法に関する。本発明は、医療用薬剤,医薬部外薬剤あるいは化粧用薬剤を皮下に配送(供給)するための装置、及び皮下への栄養供給装置,医療検査装置に利用可能である。   The present invention relates to a transdermal drug delivery device that supplies a drug subcutaneously, a transdermal drug delivery method using the device, and a method for manufacturing a needle device used in the device. INDUSTRIAL APPLICABILITY The present invention can be used for a device for delivering (supplying) a medical drug, a quasi-drug, or a cosmetic drug subcutaneously, a subcutaneous nutrient supply device, and a medical examination device.

皮膚を経由して、薬剤を皮下に配送(供給)する装置として従来利用されている技術は、注射器による皮下注射、あるいは、点滴である。折損しない程度に十分な強度をもつ金属製の注射針を皮膚に刺し、皮下組織にまで達した針先端から薬剤を体内に注入する。   A technique conventionally used as a device for delivering (supplying) a drug subcutaneously via the skin is subcutaneous injection by a syringe or infusion. A metal injection needle with sufficient strength not to break is inserted into the skin, and the drug is injected into the body from the tip of the needle reaching the subcutaneous tissue.

上記注射器等による従来方法には、皮膚を針で刺すときの痛みに加え、頻繁な使用によって皮膚組織が硬化するという短所がある。また、皮膚の表皮層または真皮層が薬剤配送のターゲットである場合には、注射針を皮膚の表面から数百μmの深さに限定して刺入することが困難であるため、期待どおりの薬剤配送効果が得られない。   The conventional method using the syringe or the like has a disadvantage that the skin tissue is hardened by frequent use in addition to pain when the skin is pierced with a needle. In addition, when the epidermis layer or dermis layer of the skin is the target for drug delivery, it is difficult to insert the injection needle to a depth of several hundred μm from the surface of the skin. Drug delivery effect is not obtained.

また皮膚の表面に軟膏等の薬剤を塗布する方法では、角質層によって薬剤の皮下への浸透が遮断される。このため、十分な量の薬剤が,表皮層や真皮層に供給されない。   In the method of applying a drug such as an ointment to the skin surface, the stratum corneum blocks the penetration of the drug into the skin. For this reason, a sufficient amount of medicine is not supplied to the epidermis layer or the dermis layer.

皮下注射や薬剤塗布とは異なる従来手法に、イオントフォレーシスとエレクトロポレーションがある(非特許文献1参照)。   Conventional methods different from subcutaneous injection and drug application include iontophoresis and electroporation (see Non-Patent Document 1).

上記イオントフォレーシスは、水溶液中で荷電した薬物を皮膚の表面に供給し、同時に、皮膚に電極を接触させて通電を行うことによって、皮下に能動的に薬物を浸透させる経皮性薬剤配送方法である。この方法では、表皮層や真皮層への薬物の吸収効率は改善されるものの、皮膚に通電するため、過電流や長期使用による皮膚刺激や皮膚障害という健康上の問題が起こり得る。   The above-mentioned iontophoresis is a transdermal drug delivery system in which a drug charged in an aqueous solution is supplied to the surface of the skin, and at the same time the electrode is brought into contact with the skin and energized to actively penetrate the drug subcutaneously. Is the method. Although this method improves the absorption efficiency of the drug into the epidermis and dermis layers, since the skin is energized, health problems such as overcurrent, skin irritation and skin damage due to long-term use may occur.

また上記エレクトロポレーションは、数百ボルトの高電圧を短時間印加することによって皮膚に形成された可逆的な微細孔を通して、薬物を皮下に導入する経皮性薬剤配送方法である。この場合も、イオントフォレーシスと同様に、通電による皮膚刺激、皮膚障害が起こり得るという問題がある。   The electroporation is a transdermal drug delivery method in which a drug is introduced subcutaneously through reversible micropores formed in the skin by applying a high voltage of several hundred volts for a short time. In this case as well, there is a problem that skin irritation and skin damage due to energization may occur as in iontophoresis.

これら従来の技術における問題を克服する経皮性薬剤配送装置として、マイクロマシン製造技術を応用して作製されるマイクロ針アレイを用いるものがある(非特許文献2参照)
上記薬剤配送装置は、多くの場合、半導体結晶または金属を材料に用いて作製される。針先端を球とすると、その直径は数μm以下、針の長さは、10〜100μm程度を最短長として自由に設計可能である。皮膚の角質層と表皮層には神経組織が存在しないので、このような微細針を表皮層に刺しても、痛みはまったく感じない。一定面積内に林立した多数の針アレイの表面に薬剤を塗布する等して、表皮層または真皮層に薬剤を供給することができる。
As a transdermal drug delivery device that overcomes the problems in these conventional techniques, there is one that uses a microneedle array that is manufactured by applying a micromachine manufacturing technique (see Non-Patent Document 2).
In many cases, the drug delivery device is manufactured using a semiconductor crystal or a metal as a material. If the tip of the needle is a sphere, the diameter can be designed to be several μm or less, and the length of the needle can be freely designed to be about 10 to 100 μm. Since there is no nerve tissue in the stratum corneum and epidermis of the skin, no pain is felt even if such fine needles are inserted into the epidermis. The drug can be supplied to the epidermis layer or the dermis layer, for example, by applying the drug to the surface of a large number of needle arrays established within a certain area.

しかしながら,これらのマイクロ針には軽視できない欠点がある。微細針は非常に細いため、皮膚への侵入時に折損し、破片が皮膚に残留する可能性がある。半導体や金属のような無機材料が皮膚に残留することは、一般に、人体の健康上有害である。また、針が折損しなかったとしても、使用後に廃棄するためには、特別な設備やプロセスが必要となる。即ち、廃棄にコストがかかる。   However, these micro needles have drawbacks that cannot be neglected. The fine needles are so thin that they can break when entering the skin and leave debris on the skin. Inorganic materials such as semiconductors and metals remaining on the skin are generally harmful to human health. Even if the needle is not broken, a special facility or process is required to dispose it after use. That is, disposal costs.

無機材料による微細針薬剤配送装置の問題点を克服し、安全で廃棄の容易な経皮性薬剤配送システムを実現する方法として、生体適合な材料を用いた微細針が考えられる(特許文献1参照)。   As a method for overcoming the problems of the fine needle drug delivery device using inorganic materials and realizing a transdermal drug delivery system that is safe and easy to dispose of, a fine needle using a biocompatible material can be considered (see Patent Document 1). ).

上記従来技術では、天然糖を材料とする微細針による薬剤配送装置が提案されている。この手法では、薬物と糖の混合物を材料として微細針が作製される。針を皮膚に刺入し、針部だけを折損して皮膚に残留させる。針部の主成分は糖であり、これは体液によって自発的に加水分解する。このとき、薬物が皮膚に放出される。天然糖は人体に安全で、水溶性であるために廃棄も容易である。
皮膚の測定・評価マニュアル集,技術情報協会,2003年,335 〜341 ページ)。 Annual Review of Biomedical Engineering, Vol.2, pp.289−313, 2000 )。 特開2003−238347号公報
In the above prior art, a drug delivery device using fine needles made of natural sugar has been proposed. In this method, a fine needle is produced using a mixture of a drug and a sugar. A needle is inserted into the skin and only the needle part is broken and left on the skin. The main component of the needle is sugar, which is hydrolyzed spontaneously by body fluids. At this time, the drug is released into the skin. Natural sugar is safe for the human body and water-soluble, so it can be easily discarded.
(Skin Measurement and Evaluation Manual, Technical Information Association, 2003, pp. 335-341). Annual Review of Biomedical Engineering, Vol.2, pp.289-313, 2000). JP 2003-238347 A

しかしながら、上記従来公報に記載された技術には、次のような決定的な問題点がある。糖は粘性が高く、流動性に乏しいために、針形状への整形や針アレイの形成が容易ではない。即ち、製造歩留まりや製造スループットが低く、製造コストが著しく高い。また、針材料への薬物の混入時に、糖の流動性を確保するためには、糖材料を100°C程度にまで加熱しなければならず、熱によって薬物が変性しやすい。更には、糖と化学反応して薬剤としての機能を失う物質は、針に混入することができない。こうして、利用可能な薬物の種類が限定される。   However, the technique described in the above conventional publication has the following critical problems. Since sugar is high in viscosity and poor in fluidity, shaping into a needle shape and formation of a needle array are not easy. That is, the manufacturing yield and manufacturing throughput are low, and the manufacturing cost is extremely high. Moreover, in order to ensure the fluidity of sugar when the drug is mixed into the needle material, the sugar material must be heated to about 100 ° C., and the drug is easily denatured by heat. Furthermore, a substance that chemically reacts with sugar and loses its function as a drug cannot be mixed into the needle. Thus, the types of drugs that can be used are limited.

本発明は、従来の経皮性薬剤配送システムに存在する問題点を克服し、人体に無痛、安全で、廃棄が容易であり、利用可能な薬物の限定が少なく、かつ、製造が容易で製造コストの安価な経皮性薬剤配送装置及び経皮性薬剤配送方法並びに針装置の製造方法を提供することを課題としている。   The present invention overcomes the problems that exist in conventional transdermal drug delivery systems, is painless to the human body, safe, easy to dispose of, has few limitations on available drugs, and is easy to manufacture An object of the present invention is to provide a transdermal drug delivery device, a transdermal drug delivery method, and a needle device manufacturing method that are inexpensive.

請求項1の発明は、ポリエチレングリコールを材料として作製された1本又は複数本の微細針を線状又は面状をなすように基板上に配列してなる針装置を備えたことを特徴とする経皮性薬剤配送装置である。   The invention of claim 1 includes a needle device in which one or a plurality of fine needles made of polyethylene glycol are arranged on a substrate so as to form a linear or planar shape. This is a transdermal drug delivery device.

請求項2の発明は、請求項1において、上記ポリエチレングリコールは分子量が1000以上であることを特徴としている。   The invention of claim 2 is characterized in that, in claim 1, the polyethylene glycol has a molecular weight of 1000 or more.

請求項3の発明は、請求項1又は2において、上記微細針は、円錐形をなし、基底部分の直径は針長の2/3又はそれ以下であることを特徴としている。   The invention of claim 3 is characterized in that, in claim 1 or 2, the fine needle has a conical shape, and the diameter of the base portion is 2/3 or less of the needle length.

請求項4の発明は、シリンダと、該シリンダ内に、出没可能にかつ没入方向に付勢されて配置された請求項1ないし3の何れかに記載の針装置と、該針装置と上記シリンダとで形成された薬剤貯留空間内に充填された薬剤とを備え、上記シリンダを皮膚に当接させた状態で上記針装置を突出させしかる後に没入させることにより皮膚に微細孔が形成されるとともに該微細孔を介して薬剤が皮下に供給されることを特徴とする経皮性薬剤配送装置である。   According to a fourth aspect of the present invention, there is provided a cylinder, the needle device according to any one of the first to third aspects, disposed in the cylinder so as to be retractable and biased in the immersion direction, the needle device, and the cylinder. And a medicine filled in the medicine storage space formed in the above, and a micropore is formed in the skin by immersing after the needle device is protruded while the cylinder is in contact with the skin. A transdermal drug delivery device characterized in that a drug is supplied subcutaneously through the micropores.

請求項5の発明は、請求項1ないし4の何れかに記載の微細針を皮膚に刺入して、表皮層または真皮層を貫通する微細孔を皮膚に一時的に形成し、該微細孔を通して皮下に薬剤を供給することを特徴とする経皮性薬剤配送方法である。   According to a fifth aspect of the present invention, the fine needle according to any one of the first to fourth aspects is inserted into the skin to temporarily form a fine hole penetrating the epidermis layer or dermis layer in the skin. A transdermal drug delivery method characterized in that a drug is supplied subcutaneously through the device.

請求項6の発明は、請求項1ないし4の何れかに記載の針装置の製造方法であって、上記微細針の反転形状を有する金型と、平坦な下面にポリエチレングリコール膜が一様な厚さに塗布形成されたプラスチック製基板とを準備し、上記金型を所定温度に加熱し、上記基板を上記ポリエチレングリコール膜が金型に押圧されるように押し付け、該金型を冷却した後、上記基板を金型から分離させることを特徴としている。   A sixth aspect of the present invention is a method for manufacturing the needle device according to any one of the first to fourth aspects, wherein a mold having a reversal shape of the fine needle and a polyethylene glycol film are uniformly formed on a flat lower surface. After preparing a plastic substrate coated and formed in a thickness, heating the mold to a predetermined temperature, pressing the substrate so that the polyethylene glycol film is pressed against the mold, and cooling the mold The substrate is separated from the mold.

ここで本発明における金型として、例えば単結晶シリコンからなるものが採用可能である。   Here, as the mold in the present invention, for example, a mold made of single crystal silicon can be adopted.

本発明では、ポリエチレングリコールを材料に用いて微細針を作製する。ポリエチレングリコールの融点は、分子量に依存するが、一般に、50°C程度で溶融して流動的となり、粘性が低く、糖と比べて加工が非常に容易であるために、微細針の製造コストが低下する。特に、剣山のように、微細針を面内に分布させて形成するのが、糖材料に比べて非常に容易である。またポリエチレングリコールは低温での加工性が良好なので、薬剤を混入する場合でも薬剤の熱変性は軽微である。   In the present invention, fine needles are produced using polyethylene glycol as a material. Although the melting point of polyethylene glycol depends on the molecular weight, generally, it melts at about 50 ° C to become fluid, has a low viscosity, and is very easy to process compared to sugar. descend. In particular, as with Kenzan, it is much easier to form fine needles distributed in the plane than sugar materials. In addition, since polyethylene glycol has good processability at low temperatures, even when a drug is mixed, thermal denaturation of the drug is slight.

薬剤を混入することなくポリエチレングリコールだけで微細針を作製し、針を皮膚に刺入して直ちに抜き取ることにより、皮膚に可逆的微細孔を形成する。この微細孔上に薬剤を塗布するか、あるいは、さらに微弱電場または圧力を加え、微細孔を通して薬剤を皮下に導入すると、微細孔のない角質上部に塗布するよりも、薬物の吸収効率が顕著に向上する。   A fine needle is made only with polyethylene glycol without mixing a drug, and the needle is inserted into the skin and immediately removed to form a reversible micropore in the skin. When a drug is applied to the micropores, or when a weak electric field or pressure is further applied and the drug is introduced subcutaneously through the micropores, the absorption efficiency of the drug is significantly higher than when applied to the upper horny layer without micropores. improves.

また微細孔を通して薬剤を導入する方法であるため、薬剤を針に混入する場合に比べて、利用可能な薬剤に対する限定が大幅に緩和される。   In addition, since the drug is introduced through the micropores, the limitation on available drugs is greatly relaxed compared to the case where the drug is mixed into the needle.

ポリエチレングリコールは、医薬品または化粧品の軟膏基剤として広く利用されており、人体に安全であることが確認されている。またポリエチレングリコールは体液と反応して自発的に溶解するので、長期間、皮膚層に残留することはない。従って仮に針が折損して皮膚に残留しても、健康上、問題はない。さらにポリエチレングリコールは水、および、アルコールのいずれにも溶解するため、使用後の廃棄は容易である。   Polyethylene glycol is widely used as an ointment base for pharmaceuticals or cosmetics and has been confirmed to be safe for the human body. Moreover, since polyethylene glycol reacts with body fluids and dissolves spontaneously, it does not remain in the skin layer for a long time. Therefore, even if the needle breaks and remains on the skin, there is no health problem. Furthermore, since polyethylene glycol is soluble in both water and alcohol, disposal after use is easy.

ポリエチレングリコールは、分子量が増加するにつれて、融点が高くなる。室温で固体とするためには、分子量が1000以上であることが望ましい。また50°C以上の高温環境でも保存できるようにしたい場合には、分子量が4000以上のポリエチレングリコールを用いる。   Polyethylene glycol has a higher melting point as the molecular weight increases. In order to obtain a solid at room temperature, the molecular weight is desirably 1000 or more. In addition, when it is desired to be able to store in a high temperature environment of 50 ° C. or higher, polyethylene glycol having a molecular weight of 4000 or more is used.

以下本発明の実施形態を添付図面に基づいて説明する。   Embodiments of the present invention will be described below with reference to the accompanying drawings.

本実施形態に係る経皮性薬剤配送装置は、ポリエチレングリコールを材料として作製された1本又は複数本の微細針を線状又は面状をなすように基板上に配列してなる針装置を備えている。   The transdermal drug delivery device according to this embodiment includes a needle device in which one or a plurality of fine needles made of polyethylene glycol are arranged on a substrate so as to form a linear or planar shape. ing.

この針装置を構成する各微細針の形状は、例えば円錐型であり、その針長は、薬剤を導入したい皮膚の深さに相当するように設計される。例えば薬剤の導入を表皮層に限定する場合には、針長は200μm以下とされる。一方、真皮層に導入する場合には、200μm以上とされる。   The shape of each fine needle constituting the needle device is, for example, a conical shape, and the needle length is designed to correspond to the depth of the skin into which the drug is to be introduced. For example, when the introduction of the drug is limited to the epidermis layer, the needle length is 200 μm or less. On the other hand, when it introduce | transduces into a dermis layer, it shall be 200 micrometers or more.

また微細針の基底部分の断面形状は円となるが、その直径は針長の2/3またはそれ以下とされる。また針間ピッチは、針長と同じかまたはそれ以上とされる。   The cross-sectional shape of the base portion of the fine needle is a circle, but its diameter is 2/3 or less of the needle length. The inter-needle pitch is equal to or greater than the needle length.

図1〜図3に基づいて、上記針装置を製造する場合の具体的な手順の一例を説明する。ただし、本発明における微細針アレイを有する針装置の製造プロセスは、この作製方法に限定されるものではない。   Based on FIGS. 1-3, an example of the concrete procedure in the case of manufacturing the said needle | hook apparatus is demonstrated. However, the manufacturing process of the needle device having the fine needle array in the present invention is not limited to this manufacturing method.

図1は、剣山のように、一定面積の面内に微細針が多数配列された微細針アレイを製造するための金型を示す。この金型1は、例えば単結晶シリコン基板からなり、微細針の反転形状を有する凹部1aが多数形成されている。なお、微細針の反転形状を単結晶シリコン基板に形成するには、既に広範に利用されている半導体シリコン集積回路製造技術、または単結晶シリコンを用いたマイクロマシンを製造するための既存の技術を用いればよい。   FIG. 1 shows a mold for producing a fine needle array in which a large number of fine needles are arranged in a plane having a constant area, such as Kenzan. The mold 1 is made of, for example, a single crystal silicon substrate, and has a large number of recesses 1a having a reversal shape of fine needles. In order to form the inverted shape of the fine needles on the single crystal silicon substrate, a semiconductor silicon integrated circuit manufacturing technique that has already been widely used or an existing technique for manufacturing a micromachine using single crystal silicon is used. That's fine.

上記金型1には、より具体的には、面積が1cm2 の正方形面内に、1mmピッチで100本の微細針の反転形状が形成されている。この場合、針長は200μm、針基底部断面の直径は100μmである。 More specifically, the mold 1 is formed with 100 fine needles having an inverted shape at a pitch of 1 mm in a square surface having an area of 1 cm 2 . In this case, the needle length is 200 μm, and the diameter of the needle base section is 100 μm.

図2は、上記微細針アレイが形成されるプラスチック製治具2を示す。この治具2は、上部が取手として利用できるように加工された基板2aを有する。この基板2aの下面は、面積1cm2 の正方形面を内包する平面となるように作製されている。この基板2aの下面には、分子量1000以上のポリエチレングリコールを一様の厚さで塗布してなる膜3が形成されている。この膜3の厚さは、針長の2倍かまたはそれ以上の厚さとされている。 FIG. 2 shows a plastic jig 2 on which the fine needle array is formed. This jig 2 has a substrate 2a processed so that the upper part can be used as a handle. The lower surface of the substrate 2a is made to be a flat surface including a square surface with an area of 1 cm 2 . On the lower surface of the substrate 2a, a film 3 is formed by coating polyethylene glycol having a molecular weight of 1000 or more with a uniform thickness. The thickness of the film 3 is twice or more than the needle length.

図3は上記金型1と治具2とを使用して針装置を作成する場合の工程の一例を示す。この例では、分子量2000のポリエチレングリコールを用いて、200μm長の針100本からなる微細針アレイを作製する。   FIG. 3 shows an example of a process for producing a needle device using the mold 1 and the jig 2. In this example, a fine needle array composed of 100 needles 200 μm long is produced using polyethylene glycol having a molecular weight of 2000.

まず上記金型1をポリエチレングリコールが流動的となる温度、例えば55°Cに加熱し、図2に例示した治具2を金型1に押し付ける(図3(a))。治具2を金型1に押し付けたたままで該金型1を冷却する(図3(b))。金型1の温度が40°C以下になったら、治具2からはみ出たポリエチレングリコールを取り除き、治具2を引き上げる(図3(c))。こうして、面積が1cm2 の正方形面内に、1mmピッチで配列された100本の微細針3aを備えた針装置2′が得られる。 First, the mold 1 is heated to a temperature at which polyethylene glycol becomes fluid, for example, 55 ° C., and the jig 2 illustrated in FIG. 2 is pressed against the mold 1 (FIG. 3A). The mold 1 is cooled while the jig 2 is pressed against the mold 1 (FIG. 3B). When the temperature of the mold 1 becomes 40 ° C. or less, the polyethylene glycol protruding from the jig 2 is removed, and the jig 2 is pulled up (FIG. 3C). In this way, a needle device 2 ′ having 100 fine needles 3a arranged at a pitch of 1 mm in a square surface having an area of 1 cm 2 is obtained.

次に、本発明による経皮性薬剤配送方法の具体例を図4(a)〜(c)に基づいて説明する。   Next, a specific example of the transdermal drug delivery method according to the present invention will be described with reference to FIGS.

まず上記200μmの微細針を備えた針装置2′を、通常の圧力で、皮膚4に押し付ける(図4(a))。ここで4aは角質層、4bは表皮層、4cは真皮層である。   First, the needle device 2 ′ having the 200 μm fine needle is pressed against the skin 4 with normal pressure (FIG. 4A). Here, 4a is a stratum corneum, 4b is an epidermis layer, and 4c is a dermis layer.

続いて針装置2′を引き上げて微細針を皮膚4から抜く。すると皮膚4に表皮層4bに達する微細孔5が一時的に形成される(図4(b))。このようにして形成された微細孔5の上部に薬剤6を供給し、該微細孔5を通して薬剤6を皮下に浸透させる(図4(c))。なお、上記微細孔5上に薬剤を塗布してもよい。また薬剤供給時に、陽極と陰極の電極を皮膚4に当て、通常のイオントフォレーシスよりも微弱な電場を印加して、薬剤の浸透を促進することができる。   Subsequently, the needle device 2 ′ is pulled up and the fine needle is removed from the skin 4. Then, micropores 5 that reach the epidermis layer 4b are temporarily formed in the skin 4 (FIG. 4B). The drug 6 is supplied to the upper part of the micropore 5 formed as described above, and the drug 6 is permeated subcutaneously through the micropore 5 (FIG. 4C). In addition, you may apply | coat a chemical | medical agent on the said fine hole 5. FIG. Further, when supplying the drug, the anode and cathode electrodes can be applied to the skin 4 and an electric field weaker than that of normal iontophoresis can be applied to promote penetration of the drug.

なお、上記薬剤配送中に、上記微細針3aが折損して皮膚に残留しても、この微細針3aは体液と反応して自己溶解するので、健康上、問題はない。しかし残留した針によって微細孔5が塞がるという問題は生じる。この問題を回避したい場合には、ポリエチレングリコールに薬剤を適当量混入させた材料を用いて微細針を作製すればよい。   Even if the fine needle 3a breaks and remains on the skin during the delivery of the medicine, the fine needle 3a reacts with the body fluid and self-dissolves, so there is no health problem. However, there arises a problem that the minute hole 5 is blocked by the remaining needle. In order to avoid this problem, a fine needle may be produced using a material obtained by mixing an appropriate amount of a drug in polyethylene glycol.

このように本実施形態では、ポリエチレングリコールを材料に用いて微細針3aを作製したので、加工が容易で製造コストを低減できる。そしてこの微細針3aの製造に当たって、本実施形態では、微細針3aの反転形状の凹部1aを有する金型1を所定温度に加熱するとともにこれにポリエチレングリコール膜を押し付けるようにしたので、より一層製造コストを低減できる。   Thus, in this embodiment, since the fine needle | hook 3a was produced using polyethyleneglycol as a material, a process is easy and manufacturing cost can be reduced. In manufacturing the fine needle 3a, in the present embodiment, the mold 1 having the concave portion 1a having the inverted shape of the fine needle 3a is heated to a predetermined temperature and pressed with a polyethylene glycol film. Cost can be reduced.

即ち、ポリエチレングリコールの融点は、分子量に依存するが、一般に、50°C程度で溶融して流動的となり、粘性が低く、糖と比べて加工が非常に容易である。その結果、微細針3aの製造コストが低下する。特に、剣山のように、微細針を面内に分布させて形成するのが、糖材料に比べて非常に容易である。またポリエチレングリコールは低温での加工性が良好なので、薬剤を混入する場合でも薬剤の熱変性は軽微である。   That is, although the melting point of polyethylene glycol depends on the molecular weight, generally it melts and becomes fluid at about 50 ° C., has a low viscosity, and is very easy to process compared to sugar. As a result, the manufacturing cost of the fine needle 3a is reduced. In particular, as with Kenzan, it is much easier to form fine needles distributed in the plane than sugar materials. In addition, since polyethylene glycol has good processability at low temperatures, even when a drug is mixed, thermal denaturation of the drug is slight.

また本実施形態では、薬剤を混入することなくポリエチレングリコールだけで微細針3aを作製し、この微細針3aを皮膚に刺入して直ちに抜き取ることにより、皮膚に可逆的な微細孔5を形成し、微細孔5上に薬剤を供給するようにしたので、微細孔のない角質上部に塗布するよりも、薬剤の吸収効率を顕著に向上させることができる。さらに微弱電場または圧力を加えた場合には、薬剤を微細孔を通してより一層効率的に皮下に供給することができる。   Moreover, in this embodiment, the fine needle 3a is produced only with polyethylene glycol without mixing a medicine, and the fine needle 3a is inserted into the skin and immediately removed, thereby forming a reversible fine hole 5 in the skin. Since the drug is supplied onto the micropores 5, the drug absorption efficiency can be remarkably improved as compared with the case where the drug is applied to the upper horny layer having no micropores. Furthermore, when a weak electric field or pressure is applied, the drug can be more subcutaneously supplied through the micropores.

図5は、図4で説明した経皮性薬剤配送方法を簡単な操作で実行できるようにした経皮性薬剤配送装置の具体例を示す。この薬剤配送装置7は、円筒状で下端が開口したシリンダ8と、該シリンダ8内に上下動可能に配設された上述の針装置2′とを備えている。この針装置2′は、微細針3aがシリンダ8の下端面8cから下方に突出可能に配置され、かつばね9により内方に没入するよう付勢されている。なお、8aは針装置2′の没入位置を規制するストッパである。   FIG. 5 shows a specific example of a transdermal drug delivery device which can execute the transdermal drug delivery method described in FIG. 4 with a simple operation. The medicine delivery device 7 includes a cylinder 8 having a cylindrical lower end and an opening at the lower end, and the needle device 2 ′ disposed in the cylinder 8 so as to be movable up and down. The needle device 2 ′ is arranged so that the fine needle 3 a can protrude downward from the lower end surface 8 c of the cylinder 8, and is biased so as to be immersed inward by a spring 9. Reference numeral 8a denotes a stopper that regulates the immersion position of the needle device 2 '.

そして上記シリンダ8と針装置2′で囲まれた空間は薬剤貯留室8aとなっており、該貯留室8aには薬剤6が充填されている。なお11は薬剤を上記貯留室8a内に注入する薬剤注入口である。   A space surrounded by the cylinder 8 and the needle device 2 'is a medicine storage chamber 8a, and the storage chamber 8a is filled with the medicine 6. Reference numeral 11 denotes a drug injection port for injecting a drug into the storage chamber 8a.

また上記針装置2′には操作棒10がシリンダ上方に突出するように配設されており、該操作棒10を押し込むと上記微細針3aが下方に突出し、操作力を緩めると内方に没入するようになっている。   The needle device 2 'is provided with an operating rod 10 that protrudes upward from the cylinder. When the operating rod 10 is pushed in, the fine needle 3a protrudes downward, and when the operating force is loosened, it is inwardly immersed. It is supposed to be.

上記薬剤配送装置7を皮膚上に配置し、針装置2′に操作棒10を介して指で通常の圧力を加える。すると針装置2′が下方に移動し、微細針3aが皮膚に刺入する。このとき、針装置2′の基板2aはストッパー8aから離れ、薬剤が皮膚上部に供給される。操作棒10に圧力を加えるのを止めると、微細針3aはばね9の復元力によって皮膚から離れ、皮膚に微細孔が形成される。この微細孔を通して、薬剤は皮下に浸透する。なお、シリンダの下面に電極を取り付けると、微弱電場によってイオントフォレーシスと同等な効果を得ることができる。   The drug delivery device 7 is placed on the skin, and a normal pressure is applied to the needle device 2 ′ with a finger through the operation bar 10. Then, the needle device 2 'moves downward, and the fine needle 3a is inserted into the skin. At this time, the substrate 2a of the needle device 2 'is separated from the stopper 8a, and the medicine is supplied to the upper part of the skin. When the pressure on the operating rod 10 is stopped, the fine needle 3a is separated from the skin by the restoring force of the spring 9, and a fine hole is formed in the skin. Through this micropore, the drug penetrates subcutaneously. If an electrode is attached to the lower surface of the cylinder, an effect equivalent to that of iontophoresis can be obtained by a weak electric field.

このように本実施形態装置7を用いた場合には、操作棒10に指で通常の力を加えて、しかる後に元に戻すだけで、微細孔5の形成と、薬剤6の供給を行なうことができ、非常に簡単な操作で経皮性薬剤配送を実現できる。   Thus, when this embodiment apparatus 7 is used, formation of the micropore 5 and supply of the chemical | medical agent 6 are performed only by applying normal force with the finger | toe to the operation stick | rod 10, and returning after that. The transdermal drug delivery can be realized with a very simple operation.

本発明の一実施形態に係る経皮性薬剤配送装置の微細針を成形するための金型の模式断面図である。It is a schematic cross section of the metal mold | die for shape | molding the fine needle of the transdermal drug delivery device which concerns on one Embodiment of this invention. 上記微細針を成形するための治具の模式断面図である。It is a schematic cross section of the jig | tool for shape | molding the said fine needle. 上記針装置の製造工程を説明するための模式工程図である。It is a schematic process diagram for demonstrating the manufacturing process of the said needle | hook apparatus. 上記針装置を用いた経皮性薬剤配送方法を説明するための模式工程図である。It is a schematic process diagram for explaining a transdermal drug delivery method using the needle device. 本発明の他の実施形態に係る経皮性薬剤配送装置の模式断面図である。It is a schematic cross section of the transdermal drug delivery device concerning other embodiments of the present invention.

符号の説明Explanation of symbols

1 金型
2 治具
2a 基板
2′ 針装置
2a 基板
3 ポリエチレングリコール膜
3a 微細針
4 皮膚
4b 表皮層
4c 真皮層
5 微細孔
6 薬剤
7 経皮性薬剤配送装置
8 シリンダ
8b 薬剤貯留空間
1 Mold 2 Jig 2a Substrate 2 'Needle device 2a Substrate 3 Polyethylene glycol film 3a Fine needle 4 Skin 4b Skin layer 4c Dermal layer 5 Fine hole 6 Drug 7 Transdermal drug delivery device 8 Cylinder 8b Drug storage space

Claims (6)

ポリエチレングリコールを材料として作製された1本又は複数本の微細針を線状又は面状をなすように基板上に配列してなる針装置を備えたことを特徴とする経皮性薬剤配送装置。   A transdermal drug delivery device comprising a needle device in which one or a plurality of fine needles made of polyethylene glycol are arranged on a substrate in a linear or planar shape. 請求項1において、上記ポリエチレングリコールは分子量が1000以上であることを特徴とする経皮性薬剤配送装置。   The transdermal drug delivery device according to claim 1, wherein the polyethylene glycol has a molecular weight of 1000 or more. 請求項1又は2において、上記微細針は、円錐形をなし、基底部分の直径は針長の2/3又はそれ以下であることを特徴とする経皮性薬剤配送装置。   The transdermal drug delivery device according to claim 1 or 2, wherein the fine needle has a conical shape, and the diameter of the base portion is 2/3 or less of the needle length. シリンダと、該シリンダ内に、出没可能にかつ没入方向に付勢されて配置された請求項1ないし3の何れかに記載の針装置と、該針装置と上記シリンダとで形成された薬剤貯留空間内に充填された薬剤とを備え、上記シリンダを皮膚に当接させた状態で上記針装置を突出させしかる後に没入させることにより、上記皮膚に微細孔が形成されるとともに該微細孔を介して薬剤が皮下に供給されることを特徴とする経皮性薬剤配送装置。   A medicine storage formed by a cylinder, the needle device according to any one of claims 1 to 3 disposed in the cylinder so as to be retractable and urged in an immersion direction, and the needle device and the cylinder. A microscopic hole is formed in the skin by inserting the needle device in a state where the cylinder is in contact with the skin and then immersing the needle device in a state where the cylinder is in contact with the skin. A transdermal drug delivery device characterized in that the drug is supplied subcutaneously. 請求項1ないし4の何れかに記載の微細針を皮膚に刺入して、表皮層または真皮層を貫通する微細孔を皮膚に一時的に形成し、該微細孔を通して皮下に薬剤を供給することを特徴とする経皮性薬剤配送方法。   The microneedle according to any one of claims 1 to 4 is inserted into the skin, a micropore penetrating the epidermis or dermis layer is temporarily formed in the skin, and the drug is supplied subcutaneously through the micropore. A transdermal drug delivery method characterized by the above. 請求項1ないし4の何れかに記載の針装置の製造方法であって、上記微細針の反転形状を有する金型と、平坦な下面にポリエチレングリコール膜が一様な厚さに塗布形成されたプラスチック製基板とを準備し、上記金型を所定温度に加熱し、上記基板を上記ポリエチレングリコール膜が金型に押圧されるように押し付け、該金型を冷却した後、上記基板を金型から分離させることを特徴とする経皮性薬剤配送装置用針装置の製造方法。   5. The method of manufacturing a needle device according to claim 1, wherein a polyethylene glycol film is applied and formed to a uniform thickness on the mold having the inverted shape of the fine needle and a flat lower surface. A plastic substrate is prepared, the mold is heated to a predetermined temperature, the substrate is pressed so that the polyethylene glycol film is pressed against the mold, the mold is cooled, and then the substrate is removed from the mold. A method of manufacturing a needle device for a transdermal drug delivery device, characterized by separating the needle device.
JP2005227584A 2005-08-05 2005-08-05 Transdermal drug delivery device and method for manufacturing needle device for transdermal drug delivery device Expired - Fee Related JP4804827B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005227584A JP4804827B2 (en) 2005-08-05 2005-08-05 Transdermal drug delivery device and method for manufacturing needle device for transdermal drug delivery device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005227584A JP4804827B2 (en) 2005-08-05 2005-08-05 Transdermal drug delivery device and method for manufacturing needle device for transdermal drug delivery device

Publications (2)

Publication Number Publication Date
JP2007037885A true JP2007037885A (en) 2007-02-15
JP4804827B2 JP4804827B2 (en) 2011-11-02

Family

ID=37796389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005227584A Expired - Fee Related JP4804827B2 (en) 2005-08-05 2005-08-05 Transdermal drug delivery device and method for manufacturing needle device for transdermal drug delivery device

Country Status (1)

Country Link
JP (1) JP4804827B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009083125A (en) * 2007-09-27 2009-04-23 Fujifilm Corp Method and apparatus for producing functional film
JP2009225987A (en) * 2008-03-21 2009-10-08 Toppan Printing Co Ltd Acicular body
WO2009130926A1 (en) * 2008-04-22 2009-10-29 南部化成株式会社 Endermic method, needle organizer and endermic injector device
JP2010188681A (en) * 2009-02-20 2010-09-02 Toppan Printing Co Ltd Manufacturing method and apparatus of needle-like structure, and needle-like structure
WO2010085031A3 (en) * 2009-01-20 2010-09-16 (주)마이티시스템 Container for delivering effective ingredients to the skin using micro-needles
WO2010126174A1 (en) 2009-05-01 2010-11-04 Nanbu Plastics Co., Ltd. Transdermal administration device
JPWO2014077244A1 (en) * 2012-11-13 2017-01-05 富士フイルム株式会社 Method for producing transdermal absorption sheet
WO2024005176A1 (en) * 2022-06-30 2024-01-04 リンテック株式会社 Microneedle structure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501163A (en) * 1999-06-09 2003-01-14 ザ プロクター アンド ギャンブル カンパニー Intracutaneous blade-shaped microneedle structure
WO2004000389A2 (en) * 2002-06-25 2003-12-31 Sung-Yun Kwon Rapidly dissolving micro-perforator for drug delivery and other applications
JP2004065775A (en) * 2002-08-08 2004-03-04 Sanwa Kagaku Kenkyusho Co Ltd Device equipped with needle-like structure element

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501163A (en) * 1999-06-09 2003-01-14 ザ プロクター アンド ギャンブル カンパニー Intracutaneous blade-shaped microneedle structure
WO2004000389A2 (en) * 2002-06-25 2003-12-31 Sung-Yun Kwon Rapidly dissolving micro-perforator for drug delivery and other applications
JP2004065775A (en) * 2002-08-08 2004-03-04 Sanwa Kagaku Kenkyusho Co Ltd Device equipped with needle-like structure element

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009083125A (en) * 2007-09-27 2009-04-23 Fujifilm Corp Method and apparatus for producing functional film
JP2009225987A (en) * 2008-03-21 2009-10-08 Toppan Printing Co Ltd Acicular body
WO2009130926A1 (en) * 2008-04-22 2009-10-29 南部化成株式会社 Endermic method, needle organizer and endermic injector device
JP2010184102A (en) * 2008-04-22 2010-08-26 Nanbu Plastics Co Ltd Endermic injector device, and needle organizer used for the same
WO2010085031A3 (en) * 2009-01-20 2010-09-16 (주)마이티시스템 Container for delivering effective ingredients to the skin using micro-needles
JP2010188681A (en) * 2009-02-20 2010-09-02 Toppan Printing Co Ltd Manufacturing method and apparatus of needle-like structure, and needle-like structure
WO2010126174A1 (en) 2009-05-01 2010-11-04 Nanbu Plastics Co., Ltd. Transdermal administration device
US8690838B2 (en) 2009-05-01 2014-04-08 Nanbu Plastics Co., Ltd. Transdermal administration device
JPWO2014077244A1 (en) * 2012-11-13 2017-01-05 富士フイルム株式会社 Method for producing transdermal absorption sheet
WO2024005176A1 (en) * 2022-06-30 2024-01-04 リンテック株式会社 Microneedle structure

Also Published As

Publication number Publication date
JP4804827B2 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
JP6928735B2 (en) Hollow microneedle with beveled opening
US9302903B2 (en) Microneedle devices and production thereof
US10099043B2 (en) Hollow microneedle array article
CN107206221B (en) Microneedle arrays and methods of use
US8043250B2 (en) High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
EP3021930B1 (en) Hollow microneedle with beveled tip
US6607513B1 (en) Device for withdrawing or administering a substance and method of manufacturing a device
AU2009249610B2 (en) Method of manufacturing solid solution perforator patches and uses thereof
EP2056921B1 (en) High-aspect-ratio microdevices for transdermal delivery and sampling of active substances
EP2343101A1 (en) Stamper for microneedle sheet, method for manufacturing the stamper, and method for manufacturing microneedle using the stamper
WO2015009531A1 (en) Article comprising a microneedle
US9717451B2 (en) Device for withdrawing or administering a substance and method of manufacturing a device
JP4804827B2 (en) Transdermal drug delivery device and method for manufacturing needle device for transdermal drug delivery device
Sarkar et al. Fabrication of microneedles using wire electric discharge machining and improving surface quality by electrochemical polishing
WO2006132602A1 (en) Polymeric microneedle array and apparatus and method for manufacturing of the same
Haider et al. A method for the rapid fabrication of solid metal microneedles
Donnelly et al. Microstructured devices for transdermal drug delivery and minimally-invasive patient monitoring
JP2018135286A (en) Uneven structure, percutaneous administration device, and percutaneous administration device set
Kaushik et al. Microneedles–minimally invasive transdermal delivery technology
Longo et al. Silicon microneedles for transdermal applications by electrochemical micromachining technology
Singh et al. Microporation and nanoporation for effective delivery of drugs and genes
Veena MICRONEEDLES: AN EMERGING TRANSDERMAL DRUG DELIVERY SYSTEM
JP2002085561A (en) Liquid injection needle
CA2696956A1 (en) Stamper for microneedle sheet, production method thereof, and microneedle production method using stamper
AU2002253812A1 (en) Microneedle devices and production thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110802

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110810

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees